Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals
Executive Summary
Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.
You may also be interested in...
Sawai's Upsher-Smith Snaps Up Dr Reddy’s Branded Migraine Assets
Upsher-Smith has acquired US and other territory rights to two specialty product assets of Dr Reddy’s, which appears to be tweaking the commercialization approach of its proprietary products business.
Upsher-Smith Snaps Up Migraine Assets As Dr Reddy’s Hones Focus
Upsher-Smith has acquired US and other territory rights to two specialty product assets of Dr Reddy’s, which appears to be tweaking the commercialization approach of its proprietary products business.
Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant
France's Poxel has completed the out-licensing of its oral Phase III-ready diabetes therapy, the glimin, imeglimin, that could be transformative for both the biotech and the US and European licensee, Roivant Sciences.
Need a specific report? 1000+ reports available
Buy Reports